研究者詳細 - 宮原　信明

論文 - 宮原　信明

分割表示 179 件中 1 - 20 件目／全件表示 >>

Practical Guidelines for Asthma Management (PGAM): Digest edition. 国際誌

Jun Tamaoki, Hiroyuki Nagase, Hiroyuki Sano, Takeshi Kaneko, Yasuhiro Gon, Nobuaki Miyahara, Hironori Sagara, Akihiko Tanaka, Takahiko Horiguchi, Etsuko Tagaya, Tomohiro Akaba, Yuji Tohda

Respiratory investigation 63 ( 3 ) 405 - 421 2025年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

The international and national guidelines for asthma management are typically comprehensive and designed for respiratory specialists, making them less practical for primary care physicians who handle most asthma cases. Recognizing the need for more accessible guidelines, the Japan Asthma Society developed the Practical Guidelines for Asthma Management (PGAM). PGAM aims to provide a concise summary of key asthma management principles, increasing awareness, education, and support among nonspecialists and patients alike. It includes user-friendly tables and lists outlining common symptoms, triggers, diagnostic criteria, and basic management strategies, along with frequently encountered treatable traits and comorbidities. These elements are presented through simple, clinically relevant algorithms. A notable feature of PGAM is the "Basic Roadmap for Asthma Management," which outlines a clear sequence for patient assessment, diagnosis, and treatment from initial consultation onward, offering an easy-to-follow visual guide. Additionally, the guidelines include methods for assessing airway inflammation, enabling patient phenotyping and endotyping. This supports a personalized treatment approach, particularly with biologics, aimed at achieving clinical remission.

DOI： 10.1016/j.resinv.2025.03.009

PubMed

researchmap

Refractory phenotype of Aspergillus-sensitized asthma with bronchiectasis and allergic bronchopulmonary aspergillosis. 国際誌

Natsuko Nomura, Hisako Matsumoto, Koichiro Asano, Yusuke Hayashi, Akihito Yokoyama, Yoshihiro Nishimura, Naozumi Hashimoto, Takuro Sakagami, Koichi Fukunaga, Nobuyuki Hizawa, Akira Yamasaki, Hiroyuki Nagase, Noboru Hattori, Mitsuko Kondo, Norihiro Harada, Hisatoshi Sugiura, Mari Miki, Tomoki Kimura, Mikio Toyoshima, Osamu Matsuno, Hidefumi Koh, Toshiyuki Kita, Hiromi Tomioka, Keisuke Tomii, Hisashi Ohnishi, Shohei Takata, Kazunori Tobino, Shiro Imokawa, Hironobu Sunadome, Tadao Nagasaki, Tsuyoshi Oguma, Naoya Tanabe, Toyohiro Hirai

The journal of allergy and clinical immunology. Global 4 ( 1 ) 100364 - 100364 2025年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Sensitization to Aspergillus, mucus plugs, and bacterial colonization may coexist and relate to a refractory phenotype during follow-up in asthma with bronchiectasis and allergic bronchopulmonary aspergillosis (ABPA). OBJECTIVE: This study aimed to clarify the features of Aspergillus-sensitized refractory asthma with bronchiectasis and determine the refractory phenotype in this population and ABPA. METHODS: This study included cases of the oldest available Aspergillus fumigatus-specific IgE data and chest computed tomography images from a nationwide survey of refractory asthma with bronchiectasis. The characteristics of the A fumigatus-IgE positive (Af sIgE+) group were investigated and compared with its nonsensitized counterpart (Af sIgE-) and ABPA group. Cluster analysis was conducted to determine the refractory phenotype. RESULTS: The Af sIgE+ group (n = 35) demonstrated type 2 inflammation levels intermediate between the ABPA (n = 42) and Af sIgE- (n = 38) groups while exhibiting higher blood monocyte counts than the Af sIgE- group. Cluster analysis conducted in patients with ABPA and Af sIgE+ newly determined 2 clusters: one was characterized by a younger age of asthma onset with fungal detection in sputum, and the other was characterized by mucus plugs and inflammation with eosinophils and monocytes, which was significantly related to mucus plugs, airflow limitation, and trend to show exacerbation. In the latter cluster, mucus plugs persisted, and 30% yielded Pseudomonas aeruginosa in the sputum <5 years later. CONCLUSION: The refractory phenotype with persistent mucus plugs was identified in Aspergillus-sensitized refractory asthma with bronchiectasis and ABPA. Mucus plug prevention is warranted.

DOI： 10.1016/j.jacig.2024.100364

PubMed

researchmap

Advantage of spirometry over oscillometry to detect dupilumab’s effect on small airway dysfunction. 査読

Toshihiro Shirai, Keita Hirai, Taisuke Akamatsu, Kenji Mizumura, Hitoshi Sasano, Norihiro Harada, Akihiko Tanaka, Hironori Sagara, Katsunori Masaki, Koichi Fukunaga, Konomi Kobayashi, Hiroyuki Nagase, Nobuaki Miyahara, Arihiko Kanehiro, Noboru Kitamura, Naruhiko Sugihara, Junko Terada-Hirashima, Masayuki Hojo, Kazuyuki Chibana, Etsuko Tagaya, Yasuhiro Gon

Allergology International 2024年12月

The Clinical Significance of Interstitial Pneumonia with Autoimmune Features in Cryptogenic Organizing Pneumonia: A Prospective Multicenter Observational Study. 査読国際誌

Hisao Higo, Hirohisa Ichikawa, Yukako Arakawa, Yoshihiro Mori, Tomoki Tamura, Shoichi Kuyama, Chiaki Matsumoto, Keisuke Sugimoto, Noboru Hamada, Toshimitsu Suwaki, Junko Itano, Yasushi Tanimoto, Satoru Senoo, Akihiko Taniguchi, Yumi Inukai, Machiko Arita, Satoko Makimoto, Katsuhide Kojima, Takashi Matsushita, Yoshinobu Maeda, Nobuaki Miyahara

Journal of clinical medicine 13 ( 22 ) 2024年11月

担当区分：最終著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

Background: There are cases of idiopathic interstitial pneumonias (IIPs) that do not meet the diagnostic criteria for connective tissue disease but have clinical features suggestive of autoimmune process. Interstitial pneumonia with autoimmune features (IPAF) was recently proposed as a research concept for these patients. Although several prospective studies on IPAF have been conducted, its clinical significance in cryptogenic organizing pneumonia (COP) remains unclear. Methods: Patients aged ≥20 years with suspected COP were prospectively enrolled between June 2018 and December 2022. Among the enrolled patients, those diagnosed with COP based on computed tomography (CT) and bronchoalveolar lavage (BAL) findings were compared between the IPAF and non-IPAF groups. Results: A total of 56 patients were enrolled in this study. Of these, 30 were diagnosed with COP and included in the analysis. Clinical and serological features were positive in two and six patients, respectively. Each feature was exclusive, and eight patients (26.7%) were diagnosed with IPAF. There were no differences between the IPAF and non-IPAF groups in terms of clinical features, including BAL findings, laboratory data, CT findings, and clinical course. During the one-year follow-up period, the frequency of COP exacerbation did not differ between the IPAF and non-IPAF groups, and no cases of systemic autoimmune disease or death occurred in either group. Conclusions: The COP characteristics of the IPAF and non-IPAF groups are similar in all aspects, and distinguishing between the two groups may be of little significance.

DOI： 10.3390/jcm13226870

PubMed

researchmap

Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma. 査読国際誌

Kenji Mizumura, Yasuhiro Gon, Norihiro Harada, Shiho Yamada, Asami Fukuda, Ryosuke Ozoe, Shuichiro Maruoka, Sumiko Abe, Kazuhisa Takahashi, Akihiko Tanaka, Hironori Sagara, Taisuke Akamatsu, Toshihiro Shirai, Katsunori Masaki, Koichi Fukunaga, Konomi Kobayashi, Hiroyuki Nagase, Nobuaki Miyahara, Arihiko Kanehiro, Noboru Kitamura, Naruhiko Sugihara, Fumio Kumasawa, Junko Terada-Hirashima, Masayuki Hojo, Kazuyuki Chibana, Etsuko Tagaya

Allergology international : official journal of the Japanese Society of Allergology 2024年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: The therapeutic effectiveness of dupilumab for severe asthma in real-world settings is yet to be prospectively investigated across multiple institutions, and uncertainties persist regarding predictive factors for its effectiveness. We aimed to assess the effectiveness of dupilumab and identify predictors of its effectiveness in real-world settings using two type-2 biomarkers: FeNO concentration and blood eosinophil count. METHODS: This prospective multicenter study included 103 patients with severe asthma. Exacerbations and respiratory functions were monitored for 24 weeks. Asthma control was evaluated using the Asthma Control Questionnaire-5. Clinical symptoms and their impact on cough and sputum were assessed using the Cough and Sputum Assessment Questionnaire (CASA-Q). Subgroup analyses of type-2 biomarkers were conducted based on FeNO levels and blood eosinophil counts at baseline. RESULTS: Treatment with dupilumab led to a reduction in exacerbations and enhancement in asthma control, FEV1, and CASA-Q scores. FEV1 improvement was correlated with enhancement in the sputum domain of the CASA-Q. Patients exhibiting elevated FeNO levels and blood eosinophil counts demonstrated more significant enhancements in FEV1. CASA-Q sputum domain scores were significantly higher in the group with elevated eosinophil counts. Regression analysis revealed that FeNO levels and blood eosinophil counts are significant predictors of FEV1 improvement, with blood eosinophil counts also predicting sputum improvement in patients treated with dupilumab. CONCLUSIONS: Type-2 biomarkers may act as indicators of improvement in FEV1 and sputum outcomes among patients with severe asthma undergoing dupilumab treatment in real-world settings.

DOI： 10.1016/j.alit.2024.08.005

PubMed

researchmap

A Case of Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation Suspension. 査読

Taichi Ozeki, Hisao Higo, Hiroki Omori, Shunta Mori, Shin Tanaka, Go Makimoto, Kiichiro Ninomiya, Akihiko Taniguchi, Masanori Fujii, Kentaro Miyoshi, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Seiichiro Sugimoto, Katsuyuki Hotta, Masahiro Tabata, Shinichi Toyooka, Yoshinobu Maeda, Nobuaki Miyahara

Internal medicine (Tokyo, Japan) 2024年9月

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

A 55-year-old man presented to our hospital with idiopathic pulmonary fibrosis (IPF). He was registered with the Japan Organ Transplant Network the following year due to disease progression. Treatment with clarithromycin, ethambutol, and rifampicin for complications of Mycobacterium avium pulmonary disease was initiated, but sputum conversion could not be achieved. The administration of an amikacin liposome inhalation suspension (ALIS) resulted in sputum conversion, and single-lung transplantation was performed. ALIS therapy was continued after lung transplantation, and no M. avium disease was observed for 15 months. ALIS may cause M. avium pulmonary disease with additional indications for lung transplantation.

DOI： 10.2169/internalmedicine.3854-24

PubMed

researchmap

Remission of hypersensitivity pneumonitis after allogeneic hematopoietic stem cell transplantation. 査読国際誌

Yumi Inukai Motokura, Hisao Higo, Chiaki Matsumoto, Mari Uno, Kanako Fujiwara, Toshiki Terao, Satoko Makimoto, Fumiyo Higaki, Ken-Ichi Matsuoka, Fumiaki Tokioka, Yoshinobu Maeda, Nobuaki Miyahara

Respiratory investigation 62 ( 5 ) 759 - 761 2024年7月

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

A 50-year-old man was diagnosed with hypersensitivity pneumonitis caused by the environment of his bar owing to worsening symptoms, laboratory test results, and computed tomography images after an environmental inhalation challenge test. His hypersensitivity pneumonitis exacerbated despite receiving prednisolone 20 mg/day. The patient underwent allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen-matched unrelated donor for myelodysplastic syndrome. No exacerbation of hypersensitivity pneumonitis was observed after HSCT. An environmental inhalation challenge test involving exposure to his bar confirmed the remission of hypersensitivity pneumonitis after HSCT. This case demonstrates that hypersensitivity pneumonitis can be remitted by HSCT.

DOI： 10.1016/j.resinv.2024.06.007

PubMed

researchmap

Predictors of exacerbation in Japanese patients with severe asthma: Analysis of the severe asthma research program (Okayama-SARP) cohort. 査読国際誌

Hisao Higo, Akihiko Taniguchi, Satoru Senoo, Taichi Ozeki, Naoki Nakamura, Masaki Atokawa, Junko Itano, Naohiro Oda, Ryota Sunami, Yutaro Shiota, Yukako Arakawa, Yoshihiro Mori, Naomi Kunichika, Ichiro Takata, Toshimitsu Suwaki, Norihiko Nakanishi, Yasushi Tanimoto, Arihiko Kanehiro, Yoshinobu Maeda, Katsuyuki Kiura, Nobuaki Miyahara

Respiratory investigation 62 ( 4 ) 695 - 701 2024年7月

担当区分：最終著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Because exacerbation of severe asthma decreases patients' quality of life, this study aimed to identify predictive factors for asthma exacerbation. METHODS: Japanese patients with severe asthma requiring treatment according to the Global Initiative for Asthma (GINA) guidelines ≥ Step 4 between January 2018 and August 2021 were prospectively enrolled and followed up for one year at facilities participating in the Okayama Respiratory Disease Study Group (Okayama Severe Asthma Research Program). RESULTS: A total of 85 patients (29 men and 56 women) were included. The median age was 64 (interquartile range [IQR], 51-72) years. Treatment according to GINA Steps 4 and 5 was required in 29 and 56 patients, respectively, and 44 patients (51.8%) were treated with biologics. The median peripheral-blood eosinophil count, fractional exhaled nitric oxide, IgE level, and percent predicted FEV1 (%FEV1) at enrollment were 204 (IQR, 49-436)/μL, 28 (IQR, 15-43) ppb, 172 (IQR, 56-473) IU/mL, and 80.0 (IQR, 61.1-96.1) %, respectively. Exacerbation during the previous year, asthma control test (ACT) score <20, %FEV1 <60%, and serum IL-10 level >6.7 pg/mL were associated with exacerbation during the observation period. CONCLUSIONS: Exacerbation during the previous year, low ACT score, and low %FEV1 were predictive factors of future exacerbation, even in a cohort with >50% of patients treated with biologics. Furthermore, high serum IL-10 levels might be a new predictive factor.

DOI： 10.1016/j.resinv.2024.05.014

PubMed

researchmap

Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report. 査読国際誌

Hiroaki Matsuura, Hisao Higo, Tadahiro Kuribayashi, Akihiko Tamaoki, Takamasa Nakasuka, Mari Uno, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Nobuaki Miyahara, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura, Kadoaki Ohashi

Thoracic cancer 15 ( 17 ) 1390 - 1394 2024年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

DOI： 10.1111/1759-7714.15324

PubMed

researchmap

びまん性肺疾患トピック肺線維症急性増悪におけるS100A8/A9の役割の検討

中村尚季, 肥後寿夫, 妹尾賢, 尾関太一, 角南良太, 山元修成, 板野純子, 谷口暁彦, 田中彩加, 木下理恵, 阪口政清, 前田嘉信, 宮原信明

日本呼吸器学会誌 13 ( 増刊 ) 217 - 217 2024年3月

特発性器質化肺炎における自己免疫性疾患の特徴を伴う間質性肺炎(IPAF)の頻度および臨床像の検討

市川裕久, 肥後寿夫, 松岡克浩, 関祥子, 荒川裕佳子, 森由弘, 久山彰一, 松本千晶, 杉本啓介, 濱田昇, 洲脇俊充, 板野純子, 谷口暁彦, 犬飼優美, 有田眞知子, 槇本怜子, 児島克英, 宮原信明

日本呼吸器学会誌 13 ( 増刊 ) 365 - 365 2024年3月

The Role of Neuropeptide Y in Respiratory Disease Pathogenesis via the Airway Immune Response 招待査読国際誌

Junko Itano, Yoshinobu Maeda, Katsuyuki Kiura, Nobuaki Miyahara

Acta Medica Okayama 78 ( 2 ) 95 - 106 2024年2月

Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study. 査読国際誌

Kohei Miyake, Satoru Senoo, Ritsuya Shiiba, Junko Itano, Goro Kimura, Tatsuyuki Kawahara, Tomoki Tamura, Kenichiro Kudo, Tetsuji Kawamura, Yasuharu Nakahara, Hisao Higo, Daisuke Himeji, Nagio Takigawa, Nobuaki Miyahara

PloS one 19 ( 2 ) e0292507 2024年

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVE: Long-term steroid use increases the risk of developing Pneumocystis pneumonia (PcP), but there are limited reports on the relation of long-term steroid and PcP mortality. METHODS: Retrospective multicenter study to identify risk factors for PcP mortality, including average steroid dose before the first visit for PcP in non-human immunodeficiency virus (HIV)-PcP patients. We generated receiver operating characteristic (ROC) curves for 90-day all-cause mortality and the mean daily steroid dose per unit body weight in the preceding 10 to 90 days in 10-day increments. Patients were dichotomized by 90-day mortality and propensity score-based stabilized inverse probability of treatment weighting (IPTW) adjusted covariates of age, sex, and underlying disease. Multivariate analysis with logistic regression assessed whether long-term corticosteroid use affected outcome. RESULTS: Of 133 patients with non-HIV-PcP, 37 died within 90 days of initial diagnosis. The area under the ROC curve for 1-40 days was highest, and the optimal cutoff point of median adjunctive corticosteroid dosage was 0.34 mg/kg/day. Past steroid dose, underlying interstitial lung disease and emphysema, lower serum albumin and lower lymphocyte count, higher lactate dehydrogenase, use of therapeutic pentamidine and therapeutic high-dose steroids were all significantly associated with mortality. Underlying autoimmune disease, past immunosuppressant use, and a longer time from onset to start of treatment, were associated lower mortality. Logistic regression analysis after adjusting for age, sex, and underlying disease with IPTW revealed that steroid dose 1-40 days before the first visit for PcP (per 0.1 mg/kg/day increment, odds ratio 1.36 [95% confidence interval = 1.16-1.66], P<0.001), low lymphocyte counts, and high lactate dehydrogenase revel were independent mortality risk factor, while respiratory failure, early steroid, and sulfamethoxazole/trimethoprim for PcP treatment did not. CONCLUSION: A steroid dose before PcP onset was strongly associated with 90-day mortality in non-HIV-PcP patients, emphasizing the importance of appropriate prophylaxis especially in this population.

DOI： 10.1371/journal.pone.0292507

PubMed

researchmap

Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy. 査読国際誌

Masahiro Yamashita, Hisao Higo, Nobuharu Fujii, Chiaki Matsumoto, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Nobuaki Miyahara

Respiratory medicine case reports 51 102104 - 102104 2024年

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she experienced persistent fatigue and cough and fever in June. Computed tomography revealed bilateral ground-glass opacities (GGO), and the patient was treated with corticosteroids for organizing pneumonia after COVID-19. Partial improvement was observed, but new GGO appeared despite corticosteroid therapy. Genome analysis of severe acute respiratory syndrome coronavirus 2 detected Omicron variant BA.1.1.2, which was prevalent at the time of initial infection. The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.

DOI： 10.1016/j.rmcr.2024.102104

PubMed

researchmap

Dramatic Response to Tezepelumab as an Initial Biologic Agent for Refractory Asthma Associated with Type 2 and Non-type 2 Traits. 査読

77 ( 6 ) 671 - 674 2023年12月

Pulmonary fibrosis and type-17 immunity. 招待査読国際誌

Satoru Senoo, Hisao Higo, Akihiko Taniguchi, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara

Respiratory investigation 61 ( 5 ) 553 - 562 2023年9月

担当区分：最終著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

Fibrosis of the lung can occur in idiopathic pulmonary fibrosis, collagen vascular diseases, and hypersensitivity pneumonitis, among other diseases. Transforming growth factor (TGF)-β, vascular epithelial growth factor, fibroblast growth factor, and platelet-derived growth factor contribute to the pathophysiology of fibrosis. TGF-β and other cytokines, including interleukin (IL)-1β, IL-6, and IL-23, activate type-17 immunity, which is involved in pulmonary fibrosis. The components of type-17 immunity include type-17 helper T cells, γδT cells, IL-17A-producing CD8-positive T cells, invariant NKT cells, and group 3 innate lymphoid cells. IL-17A, the main cytokine of type-17 immunity, is able to induce the epithelial-mesenchymal transition in epithelial cells via a production of TGF-β, directly stimulate fibroblasts and fibrocytes, and inhibit autophagy, which otherwise protects against pulmonary fibrosis. IL-23 induces type-17 immunity and plays an important role in the acute exacerbation of pulmonary fibrosis. Clinical studies have also linked type-17 immunity to the pathogenesis of pulmonary fibrosis. Consequently, targeting type-17 immunity may serve as a new therapeutic strategy to prevent the development or exacerbation of pulmonary fibrosis.

DOI： 10.1016/j.resinv.2023.05.005

PubMed

researchmap

Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study. 査読国際誌

Hisao Higo, Hirohisa Ichikawa, Yukako Arakawa, Yoshihiro Mori, Junko Itano, Akihiko Taniguchi, Satoru Senoo, Goro Kimura, Yasushi Tanimoto, Kohei Miyake, Tomoya Katsuta, Mikio Kataoka, Yoshinobu Maeda, Katsuyuki Kiura, Nobuaki Miyahara, Okayama Respiratory Disease Study Group Ordsg

Journal of clinical medicine 12 ( 16 ) 2023年8月

担当区分：最終著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Dupilumab is a fully humanized monoclonal antibody that blocks interleukin-4 and interleukin-13 signals. Several large clinical trials have demonstrated the efficacy of dupilumab in patients with severe asthma. However, few studies have examined a switch to dupilumab from other biologics. METHODS: This retrospective, multi-center observational study was conducted by the Okayama Respiratory Disease Study Group. Consecutive patients with severe asthma who were switched to dupilumab from other biologics without a treatment interval between May 2019 and September 2021 were enrolled. Patients with a treatment interval of more than twice the standard dosing interval for the previous biologic prior to dupilumab administration were excluded. RESULTS: The median patient age of the 27 patients enrolled in this study was 57 years (IQR, 45-68 years). Eosinophilic chronic rhinosinusitis (ECRS)/chronic rhinosinusitis with nasal polyp (CRSwNP) was confirmed in 23 patients. Previous biologics consisted of omalizumab (n = 3), mepolizumab (n = 3), and benralizumab (n = 21). Dupilumab significantly improved FEV1 (median improvement: +145 mL) and the asthma control test score (median improvement: +2). The overall response rate in patients receiving dupilumab for asthma as determined using the Global Evaluations of Treatment Effectiveness (GETE) was 77.8%. There were no significant differences in the baseline characteristics of the GETE-improved group vs. the non-GETE-improved group. ECRS/CRSwNP improved in 20 of the 23 patients (87.0%). Overall, 8 of the 27 patients (29.6%) developed transient hypereosinophilia (>1500/μL), but all were asymptomatic and able to continue dupilumab therapy. CONCLUSIONS: Dupilumab was highly effective for the treatment of severe asthma and ECRS/CRSwNP, even in patients switched from other biologics without a treatment interval.

DOI： 10.3390/jcm12165174

PubMed

researchmap

抗IL-4受容体抗体 GETEを用いた重症喘息におけるデュピルマブの効果予測因子の検討 iPOT4R多施設共同研究

水村賢司, 鹿野壯太郎, 正木克宜, 福永興壱, 原田紀宏, 田中明彦, 小林このみ, 長瀬洋之, 多賀谷悦子, 宮原信明, 赤松泰介, 白井敏博, 金廣有彦, 杉原徳彦, 北村登, 熊澤文雄, 寺田純子, 放生雅章, 知花和行, 權寧博

アレルギー 72 ( 6-7 ) 907 - 907 2023年8月

抗IL-4受容体抗体他の生物学的製剤からデュピルマブへ切り替えた喘息症例に関する多施設共同後ろ向き観察研究

肥後寿夫, 角南良太, 市川裕久, 荒川裕佳子, 森由弘, 板野純子, 木村五郎, 谷本安, 三宅剛平, 片岡幹男, 木浦勝行, 宮原信明

アレルギー 72 ( 6-7 ) 908 - 908 2023年8月

重症喘息におけるデュピルマブの喀痰症状への効果と呼吸機能の関連 iPOT4R多施設共同研究

鹿野壯太郎, 水村賢司, 權寧博, 正木克宜, 福永興壱, 原田紀彦, 田中明彦, 小林このみ, 長瀬洋之, 宮原信明, 赤松泰介, 白井敏博, 金廣有彦, 杉原徳彦, 北村登, 熊澤文雄, 寺田純子, 放生雅章, 知花和行, 多賀谷悦子

アレルギー 72 ( 6-7 ) 927 - 927 2023年8月

　前のページ - 次のページ　

<宮原 信明>

論文 - 宮原 信明

<宮原　信明>

論文 - 宮原　信明